• Precigen ActoBio announces positive topline results from Phase 1b/2a Study of AG019 ActoBiotics™

    Monday June 14th 2021

  • OXURION confirms Institutional Review Board approval and submission of the Investigational New Drug Application to the FDA to start Phase 2 Study evaluating THR-687 for Diabetic Macular Edema (DME)

    Thursday June 10th 2021

  • Biotalys nominates Catherine Moukheibir to its Board of Directors

    Thursday June 10th 2021

  • argenx to regain global rights to cusatuzumab

    Tuesday June 8th 2021

  • OXURION completes patient enrollment for Part A of Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)

    Tuesday June 8th 2021

  • SELECTION study on filgotinib in ulcerative colitis published in The Lancet

    Friday June 4th 2021

  • RheaVita closes EUR 2.5 million Series A Financing co-led by Novalis Biotech Acceleration and PMV

    Wednesday June 2nd 2021

  • argenx appoints Karl Gubitz as Chief Financial Officer

    Wednesday June 2nd 2021

  • Your news here?

  • Sequana Medical announces first patient enrolled in SAHARA DESERT

    Tuesday June 1st 2021

  • QbD Software announces major rebranding: Scilife is born

    Thursday May 27th 2021

  • Nextstellis® receives FDA marketing exclusivity and phase III data published

    Thursday May 27th 2021


Strategic Partners